For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an increased risk for renal events.

CardCash.com to Offer Cost-Effective Solutions for High-Demand GLP-1 Medications as Prescription Drug Market Grows SCHAUMBURG, IL / ACCESS Newswire / February 20, 2025 / Giftify, Inc. (NASDAQ:GIFT) (t ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

Consumer Reports warns that there are important considerations, especially for older adults, before starting these treatments ...

After pre-announcing that its full-year revenue would come in below its original guidance, Eli Lilly (NYSE: LLY) announced ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Mounjaro and Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring in popularity globally due to the amount of weight people lose while ...

Both drugs contain semaglutide at different concentrations. Ozempic is only licensed for Type 2 diabetes patients in the UK (though some doctors prescribe it off-label for weight loss), while ...

Dr. Darien Sutton and Dr. Stephanie Widmer discuss new studies, which found GLP-1 weight loss drugs beneficial in fighting Type 2 diabetes and certain addiction disorders. Semaglutide, the active ...

Mounjaro and Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring in popularity globally due to the amount of weight people lose while ...

Lilly said on a call with analysts that it still believed there was huge demand for its weight-loss drug Zepbound and diabetes treatment Mounjaro from hundreds of millions of patients. The ...

Retatrutide is a key part of Eli Lilly's drug pipeline that could help the company maintain its dominance in the blockbuster weight loss and diabetes treatment space and gain an edge over key ...